A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

About the study

The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult participants.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Males or females of non-childbearing potential, between 18 and 55 years of age
In good health, determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory assessments
Body mass index (BMI) 18 to 32 kg/m^2 (inclusive)
Cohorts 1 and 2 ethnicity requirements: none
Cohort 3 ethnicity requirements: first- or second-generation Japanese participants

EXCLUSION CRITERIA

Exclusion Criteria:

Significant history of any hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, immunologic, musculoskeletal disease, or allergic disease (as determined by the Investigator)
Any ocular condition likely to increase the risk of eye toxicity
Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300-B01
Females of child-bearing potential and males who plan to father a child while enrolled in this study